Specifically in glioma, high expression of CXCR2 correlates with high-grade glioma in patients, poor prognosis, and tumor recurrence, while inhibition of CXCR1/2 signaling with the SB225002 inhibitor reduced migration of glioma cells in vitro41. This evidence concerns the gene CXCR1 and central nervous system cancer.